Popular weight loss drugs show new promising power against wearing migraines

Beyond the control of diabetes and weight management, GLP-1 can have another benefit: helping with migraines.

In a small study, a GLP-1 medicine reduced the number of days that people spent with a migraine almost half in a certain month.

Presented at the Congress of the European Academy of Neurology in Helinski, Finland, on June 21, the results suggest that future uses promising popular obesity and diabetes.

Who should take drugs with weight loss? Doctors share the best candidates

About 40 million Americans deal with migraines, according to the World Health Organization (WHO), and for many, they are more than a headache.

Migraines are the second leading cause of disability worldwide, previous agency states, with symptoms that include severe headaches, nausea and light sensitivity often disturbing daily activities.

Previous studies have shown that GLP-1s can reduce pressure inside the skull, which is a possible cause of migraines, according to various healthcare organizations.

The neurologist and leadership of Simone Braca of the University of Naples Federico II in Italy, together with his colleagues, explored if Liraglutide, an earlier version of the Agonists of the Petptid Recipe-1 receiver similar to glucagon (GLP-1 RAS), could help migraine sufferings.

“Most patients felt better during the first two weeks and reported that the quality of life improved significantly.”

Thirty-one adults, 26 of women, obtained daily liraglutide injections for 12 weeks. The participants, who met the obesity criteria, also continued to take their current migraine drugs.

At the beginning of the experiment, participants reported about 20 days out of a month. After 12 weeks of Liraglutide, the average number dropped to about 11 days.

“Most patients felt better during the first two weeks and reported that the quality of life improved significantly,” Braca said in a statement.

The relief of the migraines lasted the full three -month observation period, said the researcher, although the weight loss was “modest and statistically non -significant”.

The weight of the participants remained at the same time during the test, suggesting that headache reductions were not linked to weight loss.

Weight loss drugs may also benefit the common medical problem, according to study

“Liaglutide is a middle-aged GLP-1, with more recent Ozempic and Mounjaro,” Dr. Sue Decotiis, a weight loss specialist certified by the Board in New York, told Fox News News.

Decotiis, who was not involved in the study, said that the liraglutide is not as effective as its most recent cousins ​​for weight loss or diabetes, and that it is not used frequently for these purposes.

“Many pharmacies do not even supply it due to the decrease in demand, but it enters the brain well enough to reduce migraines,” he said.

Potential limitations

The trials did not include a comparison group, and participants and researchers knew that everyone received Liraglutide, and the researchers said.

38% of participants took place smooth gastrointestinal side effects (mainly nausea and constipation), but did not disrupt the treatment.

Click here to get the Fox News app

Additional investigation may include other groups, such as control groups and unobesally, to compare the effects of the drug.

“The study was very small,” Decotiis confirmed to Fox News Digital.

Given their size and short duration, findings could be limited until more research was performed, according to the expert.

Click here to register -you are in our health newsletter

The researchers also tested only one medicine, Liraglutid, “which is not used as often as the general population as the semaglutide or the Tirzepatida,” added Decotiis.

For more health items, visit www.foxnews.com/health

The team then plans a random, double -blind trial that will also measure pressure inside the skull.

“We also want to determine if other GLP-1 drugs can offer the same relief, possibly with less gastrointestinal side effects,” Braca said in the same statement.